Dulaglutide Latest Research: New Indications, Trials & What’s Coming

Introduction

Dulaglutide has been on the market for 12 years as of 2026. The molecule is mature, with well-established efficacy and safety profiles. Recent research has shifted from establishing primary efficacy to exploring expanded indications, head-to-head comparisons with newer agents, and pharmacoeconomic questions tied to the Medicare price negotiation process.

This article covers what’s been published in 2024 and 2025, what’s in active trials, and how the regulatory landscape is shaping dulaglutide’s future.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Did Medicare’s Price Negotiation Announcement Mean?

The Centers for Medicare and Medicaid Services announced the second wave of Inflation Reduction Act price negotiations in January 2025. Trulicity® (dulaglutide) was on the list, along with 14 other high-spend drugs.

Quick Answer: Medicare selected Trulicity for second-wave price negotiation, MFP of 408 dollars effective 2027

The Maximum Fair Price for Trulicity, announced after negotiation completed in November 2025, is 408 dollars per month effective January 2027. That’s a 58 percent reduction from the 2025 Medicare Part D plan cost.

This pricing applies only to Medicare beneficiaries, not commercial insurance. But the negotiated price often pulls down list prices over time as Lilly faces pressure to maintain margins. Industry analysts project commercial WAC could decline 15 to 25 percent within 2 to 3 years of the Medicare MFP taking effect.

For patients, the immediate impact is improved Medicare Part D affordability starting in 2027.

What’s the Status of Biosimilar Dulaglutide?

Two ANDA applications for biosimilar dulaglutide are in FDA review as of 2026. Teva filed in 2023 and Sandoz in 2024. The FDA biosimilar review typically takes 18 to 30 months, with potential approval in late 2026 to early 2028.

Patent litigation will likely delay launch. Lilly holds multiple secondary patents on the Trulicity autoinjector device, with expiration dates ranging from 2027 to 2030. Settlement agreements between brand and biosimilar makers often establish launch dates 1 to 3 years after FDA approval.

Realistic biosimilar launch timing is 2027 to 2029. Biosimilars typically price 30 to 50 percent below the originator. For dulaglutide at current pricing, that would mean monthly cost in the 500 to 700 dollar range at brand-equivalent insurance tiers.

What Did AWARD-PEDS Show for Adolescents?

The AWARD-PEDS trial (Arslanian et al. 2022 NEJM) supported FDA approval of dulaglutide for pediatric type 2 diabetes in 2022. The trial enrolled 154 adolescents aged 10 to 17 with type 2 diabetes inadequately controlled on metformin alone, with or without basal insulin.

Dulaglutide 0.75 mg or 1.5 mg weekly produced HbA1c reductions of 0.6 and 0.9 percent respectively at 26 weeks, compared with a 0.6 percent increase on placebo. The treatment difference was statistically significant for both doses.

Mean weight change was modest. The 1.5 mg group lost 0.6 kg vs. weight gain of 0.7 kg on placebo. This is in line with adult AWARD trials showing modest weight effects relative to glycemic effects.

Pediatric type 2 diabetes is increasing as adolescent obesity rises. Dulaglutide gives clinicians another option beyond metformin and insulin for this population. Liraglutide and semaglutide are also approved for pediatric type 2 diabetes from age 10.

Are There New Indications Being Explored?

Active dulaglutide trials in 2026 are exploring:

1. Heart failure with reduced ejection fraction in patients with type 2 diabetes
2. Non-alcoholic steatohepatitis (NASH/MASH) following resmetirom approval
3. Continued cardiovascular event reduction in primary prevention
4. Postpartum weight retention in patients with gestational diabetes history

The NASH program is smaller than for semaglutide. Lilly has prioritized tirzepatide in NASH given the SYNERGY-NASH phase 2 data. Dulaglutide NASH studies are mostly investigator-initiated rather than industry-sponsored.

The heart failure indication has interest after SOUL trial data showed semaglutide reduced HF hospitalizations in type 2 diabetes. Whether dulaglutide produces similar benefit is being studied in the AWARD-HF trial, enrolling now with completion expected 2027.

What Did the REWIND Extension Show?

The REWIND long-term extension (Gerstein et al. 2025 Diabetes Care) followed 3,107 of the original 9,901 participants for an additional 4 years after the primary trial. Mean total follow-up was 9.4 years.

The MACE reduction observed in primary REWIND (12 percent over 5.4 years) was sustained at 11 percent over the extended follow-up. Mortality from cardiovascular causes was reduced by 14 percent. Heart failure hospitalization reduction was 19 percent, larger than in the primary trial.

Renal outcomes showed durable benefit. The composite renal endpoint reduction of 15 percent in the primary trial extended to 14 percent at 9.4 years. New macroalbuminuria continued to be reduced, suggesting sustained protective effect on diabetic nephropathy progression.

These data strengthen the case for continued dulaglutide therapy in type 2 diabetes patients with CV or renal risk factors, even after many years of treatment.

How Does Dulaglutide Combine with SGLT2 Inhibitors?

The DURATION-8 trial concept (originally for exenatide plus dapagliflozin) inspired similar studies with dulaglutide. The DURATION-9 trial (Mathieu et al. 2024 Lancet Diabetes Endocrinology) randomized 692 type 2 diabetes patients to dulaglutide alone, dapagliflozin alone, or the combination.

At 24 weeks, the combination produced HbA1c reduction of 1.9 percent vs. 1.4 percent on dulaglutide alone and 1.2 percent on dapagliflozin alone. Weight loss was 4.3 kg in combination vs. 2.7 kg on dulaglutide alone.

The combination is mechanistically attractive. GLP-1 agonists slow gastric emptying and suppress appetite. SGLT2 inhibitors block renal glucose reabsorption and produce mild diuresis. Cardiovascular and renal benefits from both classes appear additive in observational data.

Some payers now cover combination GLP-1/SGLT2 therapy for type 2 diabetes patients with established CVD or CKD. The combined cost is significant, but the combined benefit may justify it for selected patients.

Is There an Oral Dulaglutide?

No, and probably never. Oral GLP-1 delivery requires either small-molecule design (like Pfizer’s discontinued danuglipron or Lilly’s orforglipron) or specialized peptide absorption enhancers (like Rybelsus® for oral semaglutide).

Dulaglutide’s IgG4 Fc fragment makes oral absorption impossible. The molecule is far too large to cross intestinal epithelium intact. Manufacturing an oral version would require redesigning the molecule entirely, at which point it wouldn’t be dulaglutide anymore.

Lilly is investing in oral orforglipron rather than oral dulaglutide. Orforglipron is a small-molecule GLP-1 agonist in phase 3 trials with potential approval in 2027. If approved, it would compete with dulaglutide in the type 2 diabetes market.

What About Safety Signals From Postmarketing Surveillance?

A 2024 JAMA Internal Medicine study (Sodhi et al.) used FDA Adverse Event Reporting System data to compare GLP-1 agonists with bupropion-naltrexone for weight loss-related adverse events. Dulaglutide showed elevated risks for gastroparesis (HR 3.67), pancreatitis (HR 9.09), and bowel obstruction (HR 4.22).

These hazard ratios attracted attention but should be interpreted carefully. The absolute event rates remain very low. FAERS data has known reporting bias issues. Larger registry studies don’t show signals this strong.

A 2025 analysis from the UK CPRD database (Wang et al. Diabetes Care) found no statistically significant increase in pancreatitis rates for dulaglutide vs. matched controls. Gastroparesis was modestly elevated (HR 1.42) but with low absolute incidence.

The takeaway is that the FAERS signal reflects reporting bias more than true population risk. Patients with risk factors should be carefully evaluated. For most patients, dulaglutide’s safety profile remains favorable.

How Does Dulaglutide Compete with Newer Agents?

The GLP-1 market has shifted substantially since dulaglutide’s 2014 launch. Semaglutide for diabetes (Ozempic®) launched in 2017 and for weight loss (Wegovy®) in 2021. Tirzepatide for diabetes (Mounjaro®) launched 2022 and for weight loss (Zepbound®) in 2023.

Both newer agents produce greater HbA1c reduction and weight loss than dulaglutide at standard doses. Tirzepatide especially has become first-line in obesity medicine practices given the 20+ percent weight loss in SURMOUNT-1.

Dulaglutide retains market share for several reasons. Long safety record. Strong CV outcomes data from REWIND. Excellent tolerability profile. Once-weekly autoinjector simplicity. Pediatric approval.

In 2026, dulaglutide is positioned as a reliable, well-tolerated option for type 2 diabetes management, particularly in older adults and patients with multiple comorbidities. For aggressive weight loss goals, the newer agents have largely displaced it.

What Does the Future Hold for Dulaglutide?

Three scenarios over the next 5 years:

1. Biosimilar competition drives down cost substantially, making dulaglutide affordable for global health programs and US patients without complete coverage
2. Medicare’s negotiated price encourages continued use as a cost-effective option among GLP-1s
3. Newer agents continue to capture the weight loss market while dulaglutide remains relevant for diabetes-specific indications

The most likely outcome is a combination. Dulaglutide will likely remain available and used for the next decade, particularly in patients where its specific properties (excellent tolerability, established CV/renal data, lower cost) align with clinical needs.

For TrimRx’s weight management focus, dulaglutide doesn’t fit our patient profile. We work with semaglutide and tirzepatide because of stronger weight loss outcomes. For type 2 diabetes patients managed by primary care or endocrinology, dulaglutide remains a strong option.

Key Takeaway: Biosimilar dulaglutide products from Teva and Sandoz are in FDA review

How Is Dulaglutide Being Studied for Renal Protection?

Following the FLOW trial results for semaglutide (Perkovic et al. 2024 NEJM), there is renewed interest in dulaglutide’s renal effects. REWIND’s secondary renal composite endpoint showed 15 percent reduction, but no dedicated renal outcomes trial existed.

The DURATION-CKD trial (enrolling 2024 to 2026) is testing dulaglutide specifically in patients with type 2 diabetes and CKD stage 3-4. Primary endpoint is composite kidney outcomes (sustained eGFR decline, end-stage kidney disease, or kidney death). Results expected 2027.

If positive, this would establish dulaglutide as a renal-protective GLP-1 in addition to its cardiovascular indication, potentially expanding insurance coverage criteria for patients with diabetic kidney disease.

What’s the Latest on Dulaglutide and Dementia Risk?

Observational studies have suggested GLP-1 agonists may reduce dementia risk. A 2024 retrospective cohort study (Wang et al. JAMA Neurology) using Medicare data found dulaglutide users had 18 percent lower incidence of new-onset dementia over 5 years compared with matched controls on other diabetes medications.

The mechanism is hypothesized to involve improved cerebral insulin sensitivity, reduced neuroinflammation, and possibly direct effects of GLP-1 receptors in the brain. Definitive randomized trial evidence is lacking.

The EVOKE phase 3 trial is testing semaglutide for prevention of Alzheimer disease progression, with results expected 2026. If positive, similar dulaglutide studies may follow. For now, any cognitive benefits remain speculative pending RCT evidence.

How Does Dulaglutide Research Connect to Broader Diabetes Management Trends?

The shift in diabetes management toward outcomes-based prescribing (using cardiovascular and renal evidence to guide choice, not just glucose lowering) has elevated dulaglutide’s role compared with older diabetes medications.

The 2025 American Diabetes Association Standards of Care now recommend GLP-1 agonists as first-line therapy for type 2 diabetes patients with established CVD, CKD, or high CV risk, alongside or instead of metformin. This is a significant change from the prior metformin-first recommendation that dominated for decades.

Dulaglutide, semaglutide, and liraglutide are all listed as having strong CV evidence. The choice between them depends on individual factors including weight loss priorities, dosing preferences, and cost considerations.

What Does the Long-term Outlook for Dulaglutide Look Like?

Five-year outlook for dulaglutide in clinical practice:

1. Continued role in type 2 diabetes management, particularly for patients prioritizing CV and renal protection
2. Lower market share for weight loss as semaglutide and tirzepatide dominate that space
3. Biosimilar entry around 2027 to 2029 driving prices down 30 to 50 percent
4. Medicare negotiated pricing taking effect 2027 supporting access for beneficiaries
5. Expanded combination therapy with SGLT2 inhibitors for cardiorenal optimization

Dulaglutide’s safety record, established efficacy, and accumulating long-term data ensure continued use even as newer agents capture growth. The molecule will likely remain available and prescribed for at least the next decade.

For weight management patients specifically, TrimRx focuses on semaglutide and tirzepatide because of stronger weight loss outcomes. Take our free assessment quiz to see which option best fits your clinical situation and weight loss goals.

What Does the REWIND Data Add to Obesity Treatment Knowledge?

While REWIND was primarily a cardiovascular outcomes trial, the secondary endpoints provided useful obesity-related data. Mean weight loss of 1.5 kg over 5 years isn’t impressive in absolute terms, but the durability of weight maintenance is notable.

A 2025 secondary analysis (Smith et al. Obesity Reviews) examined REWIND participants who achieved 5 percent or greater weight loss. About 22 percent of dulaglutide users met this threshold and maintained it for 5+ years, compared with 8 percent on placebo with comparable lifestyle interventions.

The implication is that even modest dulaglutide-induced weight loss can be durable when combined with continued therapy. Discontinuation studies show partial regain after stopping dulaglutide, similar to other GLP-1 agonists. Continuous therapy is needed to maintain the benefit.

How Does Dulaglutide Compare in Head-to-head Trials?

Direct comparison trials inform clinical decision-making more reliably than indirect comparisons. Key head-to-head studies include:

1. SUSTAIN-7 (semaglutide vs. dulaglutide): semaglutide superior for HbA1c and weight
2. AWARD-6 (dulaglutide vs. liraglutide): non-inferior for HbA1c, slight liraglutide weight advantage
3. PIONEER-4 (oral semaglutide vs. liraglutide vs. placebo, indirect dulaglutide comparison): oral semaglutide non-inferior to liraglutide
4. SURPASS-2 (tirzepatide vs. semaglutide): tirzepatide superior
5. SURPASS-1 to 5 (tirzepatide vs. various comparators including standard care): tirzepatide consistently superior

The hierarchy that emerges: tirzepatide produces strongest weight loss and HbA1c reduction, followed by semaglutide, then dulaglutide and liraglutide roughly equivalent at standard doses. For specific patient situations, the choice may not follow this hierarchy strictly.

What Does the Future of Injectable GLP-1s Look Like?

The trend in 2026 is toward:

1. Higher-potency single agents (tirzepatide, retatrutide)
2. Combination products (CagriSema, others in development)
3. Oral small molecules (orforglipron approaching approval)
4. Generic and biosimilar competition reducing prices
5. Expanded indications beyond diabetes and obesity (NASH, CKD, dementia)

Dulaglutide is positioned as a mature, well-tolerated option with strong CV and renal evidence. Its market share for weight loss has declined but its diabetes indication remains strong. Generic and biosimilar entry over the next 5 years will further extend dulaglutide’s accessible role in clinical practice.

How Does TrimRx Stay Current with Research?

The TrimRx clinical team monitors:

1. Major journals (NEJM, Lancet, Diabetes Care, JAMA)
2. ADA and EASD annual meeting proceedings
3. FDA labeling updates and safety communications
4. ClinicalTrials.gov for emerging trial designs
5. Professional society guideline updates

This continuous review informs our prescribing recommendations and patient education materials. For TrimRx patients prescribed semaglutide or tirzepatide, our guidance reflects current evidence. For patients receiving dulaglutide from other providers, our team can discuss how current research affects ongoing treatment decisions.

Bottom line: Newer GLP-1s (semaglutide, tirzepatide) have captured market share for weight loss indications

FAQ

Will Dulaglutide Be Replaced by Newer GLP-1s?

Not entirely. The combination of strong CV and renal outcomes data, excellent tolerability, and the upcoming biosimilar competition will keep dulaglutide relevant for selected patients for years.

When Will Biosimilar Dulaglutide Be Available?

Realistic launch timing is 2027 to 2029, depending on FDA approval timing and patent litigation outcomes. Settlement agreements between brand and biosimilar makers typically determine specific launch dates.

Is Dulaglutide Still Being Studied for New Indications?

Yes, though investment has slowed compared with newer agents. Active trials include heart failure, NASH, postpartum weight retention, and combination therapy with SGLT2 inhibitors.

Does the Medicare Negotiated Price Affect What I Pay Now?

Not until 2027. The Maximum Fair Price of 408 dollars per month takes effect January 2027 for Medicare beneficiaries. Commercial insurance pricing isn’t directly affected but may decline over subsequent years.

Is Dulaglutide a Good Long-term Medication?

Yes for selected patients. REWIND’s 9.4-year extension data shows durable cardiovascular and renal protection with continued use. Tolerability remains good over long-term therapy. Discontinuation usually leads to gradual return of cardiometabolic risk factors.

How Can I Stay Informed About Dulaglutide Research?

ClinicalTrials.gov tracks active studies. Diabetes Care, NEJM, Lancet, and Diabetologia publish major trial results. The American Diabetes Association annual meeting (June each year) and EASD annual meeting (September) present new data. TrimRx clinicians stay current on the literature relevant to weight management with GLP-1s.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.